Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
65 results about "GDF15" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Growth/differentiation factor 15 (GDF15) was first identified as Macrophage inhibitory cytokine-1 or MIC-1. It is a protein belonging to the transforming growth factor beta superfamily. Under normal conditions, GDF-15 is expressed in low concentrations in most organs and upregulated because of injury of organs such as such as liver, kidney, heart and lung.
Biomarkers for differentiating melanoma from benign nevus in the skin
Disclosed is a method for diagnosing melanoma in a human subject, as well as a method for providing a prognosis to a human subject who is at risk of developing melanoma recurrence, and a method for determining the stage of melanoma in a human subject, comprising the step of determining the level of expression of phosphatase and actin regulator 1 (PHACTR1) gene, or fragments thereof, either alone or in combination with the level of expression of secreted integrin-binding phosphoprotein (SPP1), preferentially expressed antigen in melanoma (PRAME), growth differentiation factor 15 (GDF 15), and chemokine C-X-C motif ligand 10 (CXCL10) genes. Further, the invention relates to a diagnostic kit, comprising at least one substance for detection of the expression of PHACTR1, or fragments thereof, either alone or in combination with the detection of SPP1, PRAME, GDF15, and CXCL10, for the diagnosis or prognosis of melanoma.
Owner:ADVANCED CELL DIAGNOSTICS INC
Compositions and methods for treating pulmonary hypertension
ActiveUS20160287664A1Treating and preventing and reducing progression ratePreventing and reducing progression ratePeptide/protein ingredientsAntibody mimetics/scaffoldsRight ventricular hypertrophyBlood vessel
In some aspects, the invention teaches pharmaceutical compositions that include a TGF-beta ligand trap, and methods of using a TGF-beta ligand trap to treat, prevent, or reduce the progression rate of pulmonary hypertension (PH). The invention also provides methods of using a TGF-beta ligand trap to treat, prevent, or reduce the progression rate of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, right ventricular hypertrophy, diseases associated with excessive TGF-beta signaling, diseases associated with excessive GDF15 signaling, and diseases associated with excessive PAI-1 signaling. The invention further provides methods of using a TGF-beta ligand trap to reduce right ventricular systolic pressure in a subject.
Owner:ACCELERON PHARMA INC +1
Composition comprising mesenchymal stem cells or culture solution of mesenchymal stem cells for the prevention or treatment of neural diseases
ActiveUS20110262393A1Neurocytoxicity caused by amyloid-beta is preventedPhosphorylation of tau protein in neurons is preventedBiocideNervous disorderDiseaseCulture fluid
Provided are a pharmaceutical composition for prevention and treatment of a neural disease including at least one selected from the group consisting of mesenchymal stem cells (MSCs), a culture solution of the MSCs, activin A, PF4, decorin, galectin 3, GDF15, glypican 3, MFRP, ICAM5, IGFBP7, PDGF-AA, SPARCL1, thrombospondin-1, WISP1, progranulin, IL-4, a factor inducing expression thereof, and any combination thereof, and a method therefor.
Owner:MEDIPOST
New applications of antibody of GDF15 (Growth differentiation factor 15) protein
ActiveCN101852804AMicrobiological testing/measurementImmunoglobulins against growth factorsSerodiagnosesDisease
The invention discloses new applications of an antibody of GDF15 (Growth differentiation factor 15) protein. The invention provides the following three applications of the antibody of the GDF15 protein: 1. the application in preparing a reagent for assisting to identify a hepatitis C patient or a hepatitis B patient; 2. the application in preparing a reagent kit for assisting to identify the hepatitis C patient or the hepatitis B patient; and 3. the application in preparing a reagent kit for assisting to identify the hepatitis C progress of the hepatitis C patient, wherein the hepatitis C progress is chronic hepatitis C, hepatitis C cirrhosis or liver cancer. On the basis of the three applications, the antibody of the GDF15 protein can be prepared into three reagent kits. The reagent kit can be used for the serological diagnosis of viral hepatitis (the hepatitis C or the hepatitis B) and judging the disease progress (the chronic hepatitis C, the hepatitis C cirrhosis or the liver cancer) and for prognosis and viral hepatitis treatment monitoring and has great value for the diagnosis and the treatment of the hepatitis C and the hepatitis B.
Owner:INST OF PATHOGEN BIOLOGY CHINESE ACADEMY OF MEDICAL SCI
Novel fatty acids and their use in conjugation to biomolecules
The invention provides a conjugate comprising a biomolecule linked to a fatty acid via a linker wherein the fatty acid has the following Formulae A1, A2 or A3:wherein R1, R2, R3, R4, Ak, n, m and p are defined herein. The invention also relates to a method for manufacturing the conjugate of the invention such as GDF15 conjugate, and its therapeutic uses such as treatment or prevention of metabolic disorders or diseases, type 2 diabetes mellitus, obesity, pancreatitis, dyslipidemia, alcoholic and nonalcoholic fatty liver disease / steatohepatitis and other progressive liver diseases, insulin resistance, hyperinsulinemia, glucose intolerance, hyperglycemia, metabolic syndrome, hypertension, cardiovascular disease, atherosclerosis, peripheral arterial disease, stroke, heart failure, coronary heart disease, diabetic complications (including but not limited to chronic kidney disease), neuropathy, gastroparesis and other metabolic disorders. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
Owner:NOVARTIS AG
GDF15 as a differential marker for spondyloarthropathy
In vitro methods for differential diagnosis of spondyloarthropathy are disclosed which involve determining the levels of GDF15 in biological samples.
Owner:VLAAMS INTERUNIVERSITAIR INST VOOR BIOTECHNOLOGIE VZW
Biomarkers for differentiating melanoma from benign nevus in the skin
InactiveUS20160115555A1Nucleotide librariesMicrobiological testing/measurementAntigenBiomarker (petroleum)
Disclosed is a method for diagnosing melanoma in a human subject, as well as a method for providing a prognosis to a human subject who is at risk of developing melanoma recurrence, and a method for determining the stage of melanoma in a human subject, comprising the step of determining the level of expression of phosphatase and actin regulator 1 (PHACTR1) gene, or fragments thereof, either alone or in combination with the level of expression of secreted integrin-binding phosphoprotein (SPP1), preferentially expressed antigen in melanoma (PRAME), growth differentiation factor 15 (GDF15), and chemokine C-X-C motif ligand 10 (CXCL10) genes. Further, the invention relates to a diagnostic kit, comprising at least one substance for detection of the expression of PHACTR1, or fragments thereof, either alone or in combination with the detection of SPP1, PRAME, GDF15, and CXCL10, for the diagnosis or prognosis of melanoma.
Owner:ADVANCED CELL DIAGNOSTICS INC
Use of biomarkers in the assessment of the early transition from arterial hypertension to heart failure
InactiveUS20140065648A1Bioreactor/fermenter combinationsBiological substance pretreatmentsCardiac functioningBiomarker (petroleum)
Methods and systems for diagnosing functional and / or structural abnormalities of the heart preceding heart failure, and for predicting the risk of developing heart failure, in a subject comprising measuring a cardiac troponin in a sample and comparing the measurement to a reference value. Other markers, including GDF15 and IGFBP7 are also measured in some embodiments.
Owner:ROCHE DIAGNOSTICS OPERATIONS INC
Composition comprising mesenchymal stem cells or mesenchymal stem cell culture fluid for preventing or treating neurological diseases
InactiveCN102281883AAvoid toxicityPrevent phosphorylationNervous disorderPeptide/protein ingredientsDiseaseThrombospondin 1
Owner:MEDIPOST
Multi-target detecting method for early-stage bladder cancer
ActiveCN104141009AIncreased sensitivityImprove featuresMicrobiological testing/measurementReference genesBiomarker (petroleum)
The invention relates to a multi-target detecting method for the early-stage bladder cancer, and belongs to the technical field of biological detection. The multi-target detecting method comprises the following steps of: (1) extracting DNA contained in urea of a patient; (2) carrying out hydrosulphite conversion treatment onto the obtained DNA; (3) detecting seven marker genes including EOMES, GDF15, NID2, PCDH17, POU4F2, TCF21 and ZNF154 by virtue of methylation specific fluorescence quantitative PCR, wherein ALU-C4 is used as a reference gene; (4), judging whether the patient suffers from the early-stage bladder cancer or not according to a CT value in the step (3). The multi-target detecting method disclosed by the invention has the following advantages: a plurality of biomarker genes are adopted for joint detection, and a mode of combining a plurality of markers is applied to improve detecting sensitivity and specificity on the premise of higher specificity of each marker; specific primers are designed according to the plurality of biomarker genes.
Owner:亚能生物技术(深圳)有限公司
Gdf15 as molecular tool to monitor and enhance phenotypic stability of articular chondrocytes
InactiveUS20110300548A1Microbiological testing/measurementArtificial cell constructsArticular chondrocyteGDF15
The present invention relates to GDF15 as a molecular marker in in vitro assays determining phenotypic stability of articular chondrocytes and predicting the outcome of chondrocyte transplantation.
Owner:UNIV GENT
Growth Differentiation Factor 15 as Biomarker for Metformin
ActiveUS20190002977A1Shorten the timeOrganic active ingredientsMetabolism disorderCvd riskBiomarker (petroleum)
The present invention relates to metformin for use in treating a patient, wherein the patient exhibits an increased level of GDF15 in response to metformin treatment; to methods of identifying a patient who will benefit or who will not benefit from metformin treatment; methods of treating a patient at risk of developing or suffering from a disease or disorder comprising administering therapeutically effective amount of metformin; methods of adapting the dosage of metformin; the usage of GDF15 as biomarker for identifying a patient who will benefit or who will not benefit from metformin treatment, kits for use in identifying a patient who will benefit from metformin treatment and the use of the kits, as well as methods of treating a patient or who will not benefit from metformin treatment.
Owner:SANOFI AVENTIS DEUT GMBH +1
Human growth differentiation factor-15 magnetic particle chemiluminescence detection kit and application thereof
PendingCN113252905AHigh sensitivityImprove linearityChemiluminescene/bioluminescenceBiological material analysisEpitopeAnti antibody
The invention discloses a human growth differentiation factor-15 magnetic particle chemiluminescence detection kit and application thereof, the kit contains a liquid reagent R1 of a GDF15 monoclonal antibody 1 marked with FITC, a liquid reagent R2 of a GDF15 monoclonal antibody 2 marked with ALP, a magnetic particle reagent R3 coupled with an anti-FITC antibody, a calibration product and a quality control product, the GDF15 monoclonal antibody 1 and the GDF15 monoclonal antibody 2 are monoclonal antibodies with different antigen recognition epitopes, and the GDF15 monoclonal antibody 1 and the GDF15 monoclonal antibody 2 and a growth differentiation factor-15 can form a compound in an antibody-antigen-antibody form. The GDF15 is detected through a magnetic particle chemiluminescence method, the method is high in detection speed, high in sensitivity, large in detection flux and easy to operate in clinical detection, full-automatic operation can be achieved on a luminescence instrument, time and labor are saved, and convenience and rapidness are achieved.
Owner:北京赛诺浦生物技术有限公司 +1
Methods for inducing the differentiation of hematopoietic stem cells into megakaryocytes and platelets, and gene controlling the differentiation
ActiveUS20090324583A1Increasing and decreasing expression of geneRegulating the differentiation of hematopoieticBiocideSkeletal/connective tissue cellsStromal cellMegakaryocyte
The present invention relates to a method for inducing the differentiation of CD34+ hematopoietic stem cells into megakaryocytes and platelets, more particularly, a method for inducing the differentiation of CD34+ hematopoietic stem cells into megakaryocytes and platelets comprising the steps of coculturing CD34+ hematopoietic stem cells with stromal cells and adding the compound of Formula 1. Further, the present invention relates to a composition for detecting the differentiation of hematopoietic stem cells into megakaryocytes and platelets, comprising an agent measuring expression level of a gene that is selected from the group consisting of KLF2 (Kiruppel-like factor2), LOC138255 (OTTHUMP00000021439), GDF15 (growth differentiation factor 15) and INHBE (inhibin, betaE), a kit comprising the composition, a method for detecting the differentiation into megakaryocytes and platelets by using the marker genes, a method for regulating the differentiation into megakaryocytes and platelets, and a method for screening a candidate compound that regulates the differentiation into megakaryocytes and platelets.
Owner:EWHA UNIV IND COLLABORATION FOUND
Treatment of chronic kidney disease and other renal dysfunction using a gdf15 modulator
InactiveUS20170137506A1Reduce productionReduced kidney function kidneyAntibody mimetics/scaffoldsImmunoglobulins against growth factorsAcute hyperglycaemiaDyslipidemia
The invention provides methods and compositions for treating a subject having a renal-related disorder, such as chronic kidney disease (CKD), end stage renal failure, diabetes, insulin resistance, kidney hypertrophy, kidney hypotrophy, polycystic kidney disease, proteinuria, hyperglycemia, hyperuricemia, gout, kidney stones, hypertension or hypertensive nephropathy, dyslipidemia, anemia and / or reduced erythropoietin production, iron deficiency or hyperfiltration. The methods and compositions use or contain a composition that reduces or inhibits GDF15 activity.
Owner:AVEO PHARM INC
OPN (osteopontin), GDF15 (growth differentiation factor-15), NSE (neuron-specific enolase), TRAP5 (tartrate resistant acid phosphatase 5) and OPG (osteoprotegerin) combined diagnosis kit
ActiveCN107462720AStrong specificityHigh sensitivityDisease diagnosisBiological testingTherapeutic effectTartrate-resistant acid phosphatase
The invention relates to the field of diagnosis kits, particularly to application of OPN, GDF15, NSE, TRAP5 and OPG to preparation of early liver cancer diagnosis detecting reagents or kits. The invention also discloses a kit which is used for diagnosing early liver cancer in a combined mode by detecting content of OPN, GDF15, NSE, TRAP and OPG in plasma. The kit has the advantages of being high in specificity and sensitivity, can be applied to early diagnosis of liver cancer, therapeutic effect evaluation during treatment and post-treatment metastasis and recurrence monitoring and can provide detecting results earlier than clinical symptoms. The kit and detecting technology is mature, short in cycle and good in specificity.
Owner:SHANGHAI CHANGHAI HOSPITAL
GDF15 rapid quantitative fluorescent microsphere detection device and preparation method thereof
ActiveCN111638364ANovel structureStrong specificityBiological material analysisBiological testingCellulosePolythylene glycol
The invention relates to a GDF15 rapid quantitative fluorescent microsphere detection device and a preparation method thereof, and belongs to the field of medical detection. The device is prepared byadhering a nitrocellulose membrane with a solid phase containing a GDF15 antibody and a goat-anti-mouse IgG polyclonal antibody, glass fiber adsorbed with a fluorescent microsphere labeled GDF15 antibody, a sample pad, absorbent paper and other auxiliary materials. The preparation method comprises the following steps: pretreating a nitrocellulose membrane by adopting a polyethylene glycol glyceroltreatment solution; combining a GDF15 antibody firstly with oleic acid modified zinc sulfide nanoparticles and then adsorbing to a nitrocellulose membrane; and preparing the proper buffer solution and the sample pad treatment solution. The reaction sensitivity is effectively improved on the basis of ensuring complete release of the immunofluorescence microsphere, and under the same threshold value, the dosage of the immunofluorescence microsphere can be reduced, the cost is saved, and the complexity of production operation is not increased. The test paper is high in sensitivity, strong in specificity, simple and convenient to operate, time-saving and strong in practicability.
Owner:JILIN PROVINCE GERUISITE BIOTECHNOLOGY CO LTD
Gdf15 as biomarker for diagnosing mitochondrial diseases
InactiveUS20170010280A1Microbiological testing/measurementImmunoglobulins against growth factorsDiseaseMitochondrial disease
To obtain data associated with a mitochondrial disease, a method includes measuring the level of at least one protein selected from the group consisting of GDF15 (growth differentiation factor 15), HGF (hepatocyte growth factor), MIG (gamma interferon induction monokine), SCF (stem cell factor) and SCGF-β (stem cell growth factor beta) in a biological sample collected from a subject. The measured protein level is compared to that of control subjects and then it is checked whether or not there is difference between the protein level of the subject and that of control subjects.
Owner:KURUME UNIV SCHOOL OF MEDICINE +1
New application of growth differentiation factor 15 in assessing first-episode stroke in hypertensive patients
The invention discloses a novel use of a novel use of growth-differential factor 15 (GDF15) in assessment of first cerebral stroke of a hypertension patient. The GDF15 is used as a marker for assessment of a first cerebral stroke risk of a subject to be detected. The invention also provides a use of a reagent for detecting a GDF15 level in a detection agent or detection system for assessment of a first cerebral stroke risk of a subject to be detected and also provides a detection system for assessment of a first cerebral stroke risk of a subject to be detected. A hypertension cohort population perspective research proves that the hypertensive patient with a high baseline blood plasma GDF15 level has a high risk of first cerebral stroke and cerebral ischemic stroke.
Owner:FUWAI HOSPITAL CHINESE ACAD OF MEDICAL SCI & PEKING UNION MEDICAL COLLEGE
Use of biomarkers in the assessment of the early transition from arterial hypertension to heart failure
ActiveUS20150079615A1Bioreactor/fermenter combinationsBiological substance pretreatmentsCardiac functioningGDF15
Owner:ROCHE DIAGNOSTICS OPERATIONS INC
A multi-target detection method for early bladder cancer
ActiveCN104141009BIncreased sensitivityImprove featuresMicrobiological testing/measurementReference genesBladder cancer
The invention relates to a multi-target detecting method for the early-stage bladder cancer, and belongs to the technical field of biological detection. The multi-target detecting method comprises the following steps of: (1) extracting DNA contained in urea of a patient; (2) carrying out hydrosulphite conversion treatment onto the obtained DNA; (3) detecting seven marker genes including EOMES, GDF15, NID2, PCDH17, POU4F2, TCF21 and ZNF154 by virtue of methylation specific fluorescence quantitative PCR, wherein ALU-C4 is used as a reference gene; (4), judging whether the patient suffers from the early-stage bladder cancer or not according to a CT value in the step (3). The multi-target detecting method disclosed by the invention has the following advantages: a plurality of biomarker genes are adopted for joint detection, and a mode of combining a plurality of markers is applied to improve detecting sensitivity and specificity on the premise of higher specificity of each marker; specific primers are designed according to the plurality of biomarker genes.
Owner:亚能生物技术(深圳)有限公司
Ovarian cancer prognosis marker combination and application thereof
PendingCN110846414AImproved prognosisMicrobiological testing/measurementBiological testingGood prognosisCancer research
The invention discloses an ovarian cancer drug-resistance marker UTP23, an expression ratio of an existing gene GDF15 and related prognosis of ovarian cancers. Particularly, when the ratio is low, anovarian cancer case shows poor prognosis according to prognostic indicators such as chemotherapy sensitivity, drug resistance, satisfactory cytoreductive surgery, progression free survival and overallsurvival. When the ratio is high, an ovarian cancer patient shows good prognosis, namely, clinical therapy of the ovarian cancers includes chemotherapy and surgical therapy to provide prognosis prompt.
Owner:ZHEJIANG CANCER HOSPITAL
Novel fatty acids and their use in conjugation to biomolecules
Owner:NOVARTIS AG
Molecular reagent for screening bladder cancer by using urine
InactiveCN108130371AReliable test resultsHigh clinical positive predictive valueMicrobiological testing/measurementDNA preparationBiotechnologyFluorescence
The invention belongs to the field of biotechnology molecular diagnosis, and provides a molecular diagnosis method of noninvasive detection of bladder cancer by using urine. The method comprises the following steps of 1, urine nucleic acid extraction and purification; 2, DNA hydrosulphite conversion reaction and subsequent purification; 3, methylation specific real-time fluorescence PCR detectionon a plurality of gene promotor regions; 4, multi-gene result analysis. The steps 1 and 2 can be merged into one step. The multi-gene comprises the promotor regions of the following genes including VIM, TMEFF2, HSPA2, GDF15, ABL1, CRH, IGF2, ANXA10, UPK1B, ACTB and the like; the gene combination detection results can be used for bladder cancer diagnosis and bladder cancer recurrence rate prediction.
Owner:上海纽思格生物医学科技有限公司
Neutral monoclonal antibodies for resisting GDF15 and application of neutral monoclonal antibodies for resisting GDF15
The invention discloses two neutral monoclonal antibodies for resisting GDF15 and an application of the neutral monoclonal antibodies for resisting GDF15, and provides variable regions of a light chain and a heavy chain of antibodies G1 and G2, having neutralizing activity. Through a hybridoma technique, monoclonal antibodies for resisting GDF15 of mice are prepared, GDF15 resisting hybridoma cellstrains which can stably secrete high specificity antibodies can be screened, and high-specificity and high-affinity GDF15 resisting monoclonal antibodies are obtained by preparing ascites. A simpleand stable antibody neutralization detection system is constructed, and two GDF15 monoclonal antibodies having neutralizing activity are verified for the first time. Based on research on immunomodulation effect of GDF15, a lymphocyte and tumor cell co-culture system and a mouse-borne tumor model are established to verify inhibition of the neutral monoclonal antibodies on tumor growth based on in vitro and in vivo levels, and foundation is laid for an application of tumor immunotherapy, metabolism correlation diseases and the like.
Owner:FOURTH MILITARY MEDICAL UNIVERSITY
Treatment of congestive heart failure and other cardiac dysfunction using a gdf15 modulator
InactiveUS20170137505A1Effectively and optimally treatedReduce the amount requiredImmunoglobulins against growth factorsAntibody ingredientsCardiac dysfunctionMyopathy
The invention provides methods and compositions of treating a subject having a cardiac-related disorder such as congestive or chronic heart failure (CHF), cardiac hypertrophy, cardiac hypotrophy, and other cardiac myopathies / dystrophies. The methods comprise administering an effective amount of a composition that modulates, for example, reduces or inhibits, GDF 15 activity in the subject.
Owner:AVEO PHARM INC
Treatment of chronic kidney disease and other renal dysfunction using a gdf15 modulator
PendingUS20190292252A1Reducing one or more common comorbidities of CKDImprove kidney functionAntibody mimetics/scaffoldsImmunoglobulins against growth factorsInsulin resistanceHypertensive Nephropathy
The invention provides methods and compositions for treating a subject having a renal-related disorder, such as chronic kidney disease (CKD), end stage renal failure, diabetes, insulin resistance, kidney hypertrophy, kidney hypotrophy, polycystic kidney disease, proteinuria, hyperglycemia, hyperuricemia, gout, kidney stones, hypertension or hypertensive nephropathy, dyslipidemia, anemia and / or reduced erythropoietin production, iron deficiency or hyperfiltration. The methods and compositions use or contain a composition that reduces or inhibits GDF15 activity.
Owner:AVEO PHARM INC
Methods for inducing the differentiation of hematopoietic stem cells into megakaryocytes and platelets, and gene controlling the differentiation
ActiveUS8137970B2Increasing and decreasing expression of geneRegulating the differentiation of hematopoieticBiocideMicrobiological testing/measurementHematopoietic cellStromal cell
The present invention relates to a method for inducing the differentiation of CD34+ hematopoietic stem cells into megakaryocytes and platelets, more particularly, a method for inducing the differentiation of CD34+ hematopoietic stem cells into megakaryocytes and platelets comprising the steps of coculturing CD34+ hematopoietic stem cells with stromal cells and adding the compound of Formula 1. Further, the present invention relates to a composition for detecting the differentiation of hematopoietic stem cells into megakaryocytes and platelets, comprising an agent measuring expression level of a gene that is selected from the group consisting of KLF2 (Kiruppel-like factor2), LOC138255 (OTTHUMP00000021439), GDF15 (growth differentiation factor 15) and INHBE (inhibin, betaE), a kit comprising the composition, a method for detecting the differentiation into megakaryocytes and platelets by using the marker genes, a method for regulating the differentiation into megakaryocytes and platelets, and a method for screening a candidate compound that regulates the differentiation into megakaryocytes and platelets.
Owner:EWHA UNIV IND COLLABORATION FOUND
A combined diagnostic kit for opn, gdf15, nse, trap5 and opg
ActiveCN107462720BStrong specificityHigh sensitivityDisease diagnosisBiological testingDiagnosis earlyAfter treatment
The invention relates to the field of diagnosis kits, particularly to application of OPN, GDF15, NSE, TRAP5 and OPG to preparation of early liver cancer diagnosis detecting reagents or kits. The invention also discloses a kit which is used for diagnosing early liver cancer in a combined mode by detecting content of OPN, GDF15, NSE, TRAP and OPG in plasma. The kit has the advantages of being high in specificity and sensitivity, can be applied to early diagnosis of liver cancer, therapeutic effect evaluation during treatment and post-treatment metastasis and recurrence monitoring and can provide detecting results earlier than clinical symptoms. The kit and detecting technology is mature, short in cycle and good in specificity.
Owner:SHANGHAI CHANGHAI HOSPITAL
Compositions and methods for treating pulmonary hypertension
ActiveUS20200323955A1Treating and preventing and reducing progression rateAccurate pressurePeptide/protein ingredientsAntibody mimetics/scaffoldsDiseaseFibrosis
In some aspects, the invention teaches pharmaceutical compositions that include a TGF-β ligand trap, and methods of using a TGF-β ligand trap to treat, prevent, or reduce the progression rate of pulmonary hypertension (PH). The invention also provides methods of using a TGF-β ligand trap to treat, prevent, or reduce the progression rate of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, right ventricular hypertrophy, diseases associated with excessive TGF-β signaling, diseases associated with excessive GDF15 signaling, and diseases associated with excessive PAI-1 signaling. The invention further provides methods of using a TGF-β ligand trap to reduce right ventricular systolic pressure in a subject.
Owner:ACCELERON PHARMA INC +1
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com